Rebuilding Mexico's Pharmaceutical Supply Chain

Mexico is working to strengthen pharmaceutical sovereignty by expanding domestic manufacturing, improving regulatory efficiency, and increasing supply-chain visibility, say industry experts. Heavy dependence on imported APIs creates vulnerability, while medicine waste and shortages reveal coordination gaps. Strategic public procurement, infrastructure investment, incentives, security, and regional export opportunities could transform Mexico from importer to reliable pharmaceutical supplier.

Mexico's pharmaceutical industry has spent recent years proving it can withstand disruption. The next test is whether it can build enough domestic manufacturing capacity to reduce its exposure to those disruptions in the first place, rather than absorbing them shipment by shipment. 

"The system must promote collaborative practices rather than working in silos where actors detach themselves from the equation," says Alberto Miranda, General Director, MARZAM. "A bottleneck does not simply occur when a company fails to obtain product; it happens because ecosystem actors fail to anticipate demand together to ensure the right medicine reaches the patient.” 

Much of that exposure traces back to active pharmaceutical ingredients and key starting materials, where global supply is concentrated in a handful of countries. China alone supplies roughly 70% of the precursors used to manufacture acetaminophen and, by some estimates, up to 90% of the active ingredients behind widely used antibiotics, according to a US Senate Special Committee on Aging analysis of the foreign generic pharmaceutical supply chain. 

Industry leaders emphasize that true sovereignty does not mean absolute isolation or total self-sufficiency, but rather guaranteed, intelligent access to critical medicines. For Mexico, closing that gap is less an efficiency question than a strategic one: whether the country can consolidate scattered manufacturing capabilities into the kind of concentrated production power that lets it act as a supplier to the region, not only a buyer from it.  

Building that local manufacturing power requires navigating a clear gradient of technical complexity across drug production stages. Carlos Oconitrillo, Supply Chain Management Head, Bayer Pharmaceutical Division, notes that manufacturing spans API synthesis, bulk formulation, and final conditioning. He adds that while APIs are technically complex, their low volume makes air transport economically viable. Conversely, final product conditioning involves moving high volume and mostly air, causing logistics costs to surge. Oconitrillo explains that this reality opens a clear regional window: while high-specialty therapies often remain near parent company headquarters, Mexico can capture high-volume formulation and packaging for Latin America, competing directly with emerging manufacturing hubs in Costa Rica, Guatemala, Colombia, Argentina, and Brazil.

Capturing that market, and expanding into rare domestic API synthesis, demands addressing structural barriers to investment ROI. A primary hurdle is regulatory and administrative latency across agencies like COFEPRIS, CONAGUA, CFE, and SEMARNAT, where site inclusion approvals and technology transfer authorizations can take over two years. Oconitrillo explained that Bayer is executing a MX$1.1 billion (US$65 million) expansion of its Lerma facility, but while exports to the US market can begin as early as 2027, regulatory timelines delay local domestic market supply until 2030. To draw new capital away from competing nations, industry insiders consider that Mexico must address lingering security risks, offer competitive incentives like land donations or tax offsets, and establish absolute legal, regulatory, and volume certainty.

That vulnerability shows up domestically as a logistics and visibility problem as much as a sourcing one. IMSS wrote off MX$177.4 million (US$10.5 million) in expired medicines in 2022 alone. ISSSTE reported average annual losses of MX$102 million (US$6.04 million) that same year from drugs that expired in warehouses before reaching patients, even as patients with conditions such as cancer and HIV protested shortages of those same categories of medicine. Expired stock and active shortages coexisting inside the same public health system is precisely the kind of bottleneck that stronger shared visibility and traceability between public buyers and private logistics providers are meant to prevent. 

"A bad sales forecast from a miscalculated public sector order impacts the private market as well. When there is unfulfilled public demand, patients turn to the private market, squeezing private demand planning. The volume is so massive that it can compromise overall availability across the entire market,” says Gabriel Morales, General Director at Weser Pharma.

Logistics providers and private distribution networks are already positioning for a larger role in closing that gap. Marcos Pascual, Commercial Director, ANAFARMEX, highlights that Mexico's private distribution backbone operates over 1,000 cold-chain vehicles and 250,000m² of warehouse space to move more than 2.4 billion units monthly. This infrastructure powers over 20,000 pharmacy-adjacent clinics conducting 20 million monthly consultations, providing urban populations access to medications within five to ten minutes.

Simultaneously, UPS Healthcare opened a 10,700m2 cold chain cross-dock facility in Mexico City in early 2025, certified under IATA's CEIV Pharma standard and capable of handling temperature ranges from ambient to frozen. This facility is part of a broader push by carriers to build out dedicated pharmaceutical infrastructure as demand for temperature-controlled distribution keeps rising. For a pharmaceutical sector where cold chain integrity and delivery visibility determine whether a shipment arrives usable, that kind of integrated logistics investment is a direct input into supply chain resilience, not a peripheral one.

Gabriel Obregón, Vice President of Operations for Latin America, UPS, emphasizes that Mexico’s air connectivity positions the country to serve as a strategic regional supplier and exporter of medicines and APIs across Latin America and beyond, even reaching markets like Asia within two days. He notes that real-time visibility across cold-chain logistics ensures these temperature-sensitive shipments reach patients without breakdown.

Public procurement is the lever most within Mexico's own control. Government purchases account for roughly 27% of the value of Mexico's pharmaceutical market, and the industry already generates close to 74,000 direct jobs and more than 310,000 indirect ones, touching 161 of the 259 branches that make up the country's economic input-output matrix, according to KPMG. Multi-year, predictable purchasing schedules across that public share of the market are what manufacturers say they need to justify new investment in local production, since a single-year tender cycle makes it difficult to commit capital to domestic API or finished-dose manufacturing that only pays off over a longer horizon. 

For the industry, sovereignty does not necessarily mean replacing every imported input with a domestic one. It can also mean building enough local capacity, procurement predictability, and shared visibility across public and private supply chains that a disruption originating abroad no longer determines whether a Mexican patient gets their medicine on time. Balancing that capacity against continued global sourcing, while making Mexico attractive enough to draw new pharmaceutical manufacturing investment, is the real test of whether resilience becomes sovereignty, or stays a permanent exercise in managing the next shortage.